Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 3Phase 1 2

Status

Completed 2Terminated 1

Sponsor Class

OTHER 7INDUSTRY 3NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 1Gynecologic 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 1Leukemia, Myeloid, Acute 1Carcinoma, Hepatocellular 1

Interventions

Carboplatin 273Paclitaxel 267Gemcitabine 244Bevacizumab 226Cisplatin 218pembrolizumab 214Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 100Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 81Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Bortezomib 65Ipilimumab 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × guadecitabine × Clear all
NCT01696032 2024-08-27

SGI-110

Astex Pharmaceuticals, Inc.

Phase 2 Completed
120 enrolled 22 charts
Gynecologic

Ovarian Neoplasms

NCT01752933 2024-08-27

SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)

Astex Pharmaceuticals, Inc.

Phase 2 Completed
52 enrolled 14 charts
Gastrointestinal

Carcinoma, Hepatocellular

NCT03603964 2024-08-27

Guadecitabine Extension Study

Astex Pharmaceuticals, Inc.

Phase 2 Terminated
35 enrolled 10 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡